| Name | Title | Contact Details |
|---|
GigaGen is advancing a pipeline of first-in-class biotherapeutics, including novel oncology antibody drug combinations and the world`s first recombinant polyclonal hyperimmune gammaglobulin. Behind our diverse and growing pipeline is a mission to bring forth a new generation of highly efficacious drugs, driven by an unparalleled understanding of immune dysregulation. Our proprietary antibody discovery technology quickly characterizes every cell in complex immune systems, powering our selection of drug targets, identification of drug candidates and preclinical assessment of efficacy.
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs
ReadCoor is leading the next generation of `omics` by delivering the first panomic spatial sequencing platform to the global audience of researchers, clinicians, pharma and diagnostics companies, and ultimately patients. It is accomplishing this with a fundamental new technology called FISSEQ which simultaneously enables integration of high throughput sequencing, morphometric analysis, cellular location and three dimensional spatial imaging. This uniquely powerful tool is the first and only implementation of `In-situ Sequencing` and will revolutionize the next phase in understanding the transcriptome, introducing vast new opportunities for important and meaningful clinical insight. ReadCoor will fulfill the mission with a comprehensive set of high quality services, systems and actionable information provided to research and healthcare communities worldwide. Current transcriptomic tools are cumbersome, inadequate and cannot preserve the rich panomic information contained in cellular structures. ReadCoor combines both next generation sequencing and morphometric information for the first time in a new generation sequencing platform that enables researchers to perform high throughput RNA sequencing without dissociating cells, thus preserving important cellular structures, pinpointing transcripts to individual cells in 3D, and delivering high fidelity spatial image data.
Flagship Biosciences, Inc. is a technology-driven tissue analysis services company delivering the most accurate and informative data for improved drug development and diagnostics. The company offers a full range of tissue analysis services using its award-winning technology to deliver breakthrough contextual data supported by a team of experienced pathology and scientific experts. It caters to pharmaceutical, biotechnology, and clinical diagnostic companies. Flagship Biosciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.